- Conditions
- Multiple Sclerosis
- Interventions
- All patients in the study will be treated with ocrelizumab
- Drug
- Lead sponsor
- Providence Health & Services
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 14 participants
- Timeline
- 2020 – 2023
- U.S. locations
- 2
- States / cities
- Portland, Oregon • Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Multiple Sclerosis
- Interventions
- ocrelizumab, ofatumumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 21 Years to 85 Years
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- COVID-19 Acute Respiratory Distress Syndrome
- Interventions
- Agilent Seahorse XF Cell Mito Stress Test
- Diagnostic Test
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Placebo, Ocrelizumab, Avonex
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2023
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Berkeley, California • San Francisco, California + 22 more
- Conditions
- Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Melanoma
- Interventions
- Pimonidazole
- Drug
- Lead sponsor
- Yana Najjar
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Osteosarcoma
- Interventions
- Cyclophosphamide and Sirolimus
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Multiple Sclerosis
- Interventions
- Multiple Sclerosis patients who have been on Ocrelizumab will undergo cognitive and fatigue assessments
- Other
- Lead sponsor
- Anza Memon
- Federal
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,604 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 7,466 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- 23-PPV, 13-PCV Booster, Influenza Vaccine, KLH, OCR, TT Vaccine
- Biological · Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 20
- States / cities
- Cullman, Alabama • Tucson, Arizona • Fullerton, California + 17 more
- Conditions
- Multiple Sclerosis
- Interventions
- Ocrelizumab, Placebo for Ocrelizumab
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 13
- States / cities
- New Haven, Connecticut • Washington D.C., District of Columbia • Chicago, Illinois + 10 more